Amphastar Pharmaceuticals (AMPH) EPS (Weighted Average and Diluted) (2013 - 2026)

Amphastar Pharmaceuticals' EPS (Weighted Average and Diluted) history runs 14 years deep, the most recent figure standing at $0.14 for Q1 2026.

• In Q1 2026, EPS (Weighted Average and Diluted) fell 72.55% year-over-year to $0.14; the TTM figure through Mar 2026 stood at $1.66 (down 39.86% YoY), while the FY2025 annual figure was $2.03, down 33.66% from the prior year.
• EPS (Weighted Average and Diluted) was $0.14 for Q1 2026 at Amphastar Pharmaceuticals, down from $0.51 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.91 in Q3 2023 to a low of $0.14 in Q1 2026.
• Historically, EPS (Weighted Average and Diluted) has averaged $0.56 across 5 years, with a median of $0.51 in 2025.
• The sharpest annual moves came in 2022 and 2026: EPS (Weighted Average and Diluted) surged 370.0% in 2022, then tumbled 72.55% in 2026.
• A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.65 in 2022, then grew by 6.15% to $0.69 in 2023, then climbed by 7.25% to $0.74 in 2024, then sank by 31.08% to $0.51 in 2025, then tumbled by 72.55% to $0.14 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $0.14 (Q1 2026), $0.51 (Q4 2025), and $0.37 (Q3 2025), per Business Quant data.